US 12234236

US patent 12234236, titled "GLP-1R agonist and therapeutic method thereof," was granted to Ascletis Pharma China Co Ltd.. The patent lists Bin Liang, Jinzi Jason Wu, and Bailing YANG as the inventors. The application was filed on September 13, 2024, and the patent was issued on February 25, 2025.

The abstract describes the present disclosure as GLP-1R modulating compounds that are useful for treating GLP-1R-mediated diseases or conditions.

Regarding the claims:
The complete text of the claims for US patent 12234236 is not present in the provided authoritative patent text. Therefore, a plain-language overview of each independent claim cannot be provided based solely on the given information. However, public records indicate that claims 1-9, 12-17, and 21-25 of US12234236B1 are currently being challenged.

Litigation Status:
As of April 26, 2026, US patent 12234236 is involved in Post-Grant Review (PGR) case number PGR2025-00057 before the Patent Trial and Appeal Board (PTAB) of the USPTO. The petitioner in this case is CONJUPRO BIOTHERAPEUTICS, INC., challenging the patent owner, ASCLETIS PHARMA CHINA CO. LTD.. The legal status is "Active," and the PTAB case is listed as "Pending - Instituted". There is no information from the search results indicating that this patent is currently involved in a case before the Court of Appeals for the Federal Circuit (CAFC) in 2026.